- Thermo Fisher Scientific
- Lonza
- Merck / MilliporeSigma
- FUJIFILM Irvine Scientific
- Cytiva
- Takara Bio
- BioLife Solutions
- Charles River Laboratories
- WuXi AppTec
- VectorBuilder
- Irvine Scientific
- Sartorius
- Miltenyi Biotec
- Biological Industries
- PromoCell
- CellGenix
- Thermo Fisher / Invitrogen
- Merck Millipore
- Corning Life Sciences
- HiMedia / Biological supply regional players
Market Growth
The global gene therapy cell culture media market size began at US$ 193.45 billion in 2024 and is forecast to rise to US$ 214.42 billion by 2025. By the end of 2034, it is expected to surpass US$ 541.42 billion, growing steadily at a CAGR of 10.84%.
- Advancements in Bioprocessing Technologies: Innovations such as closed-system processing and automation are improving efficiency, driving the adoption of specialized media for scalable manufacturing.
- In November 2024, Agilent Technologies reorganized its Life Sciences and Diagnostics division to strengthen its focus on cell-based solutions for research, therapy development, and diagnostics. The new structure emphasizes innovation in single-cell analysis, genomics, and cell-based assays, aiming to accelerate progress in drug discovery and cell therapies while positioning Agilent as a leader in advanced cell technologies.
- Global Expansion of Manufacturing Facilities: New facilities and CDMO investments worldwide are boosting capacity, thereby driving consistent demand for advanced cell culture media.
- In July 2024, Merck opened its first GMP-compliant cell culture media production line in Nantong, China, with an investment of about €6.6 million ($7.1 million). The new facility is designed to address growing regional demand for high-quality custom media used in biopharmaceuticals, vaccines, and therapeutic manufacturing.
R&D
Research and development in gene therapy cell culture media is centered on creating tailored, well-defined, and xeno-free formulations that enhance the growth, survival, and functional performance of genetically engineered cells. These efforts are especially focused on supporting cells used for producing viral vectors, ensuring optimal gene expression and consistent performance in therapeutic applications.
Clinical Trial
A clinical trial for gene therapy cell culture media involves testing specific media formulations to assess their effectiveness in supporting cell growth, viability, and scalability during the development of gene therapy products, while ensuring safety and consistent performance.
Regulatory Approvals
Regulatory approval for cell culture media in gene therapies requires proving safety, quality, and consistency. Agencies such as the FDA evaluate comprehensive CMC (Chemistry, Manufacturing, and Controls) data to ensure the media meets standards and poses minimal risk in therapeutic applications.
Latest Announcement by Industry Leaders
iotaSciences introduced the Single-Cell Cloning Platform XT, an enhanced version of its original system with proprietary fluid-shaping technology. The platform automates single-cell isolation, culture, and transfer to 96-well plates, offering higher throughput and documented monoclonality via the new SCAI technology. Expanding its use from stem cell and gene editing research, it now supports cell line and reporter line development. Dr. Feuerborn noted it delivers reliable, high-quality monoclonal cultures, while CEO Dr. Lutz highlighted its role in advancing single-cell biology and cell and gene therapy R&D.
- In May 2025, Germany’s PL BioScience teamed up with South Korea’s DewCell Biotherapeutics to introduce a scalable, fully animal-free human platelet lysate, providing a sustainable cell culture medium for the global cell therapy industry.
- In April 2025, Capricorn Scientific collaborated with Turkey’s Florabio AS to release animal-free, high-yield cell culture media, combining their expertise to provide scalable, well-defined formulations for biotech and vaccine research worldwide.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
